Document Type

Article

Publication Date

7-26-2022

Identifier

DOI: 10.1182/bloodadvances.2021006393

Abstract

Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Administration approved for relapsed or refractory B-ALL in patients ≤25 years; however, the safety and efficacy of this therapy in young patients is largely unknown because children(n = 14). Sixty-four percent of patients (n = 9) achieved minimal residual disease-negative remission after CART and 50% of patients remain in remission at last follow-up. All patients with high disease burden at time of CART infusion (>M1 marrow) were refractory to this therapy (n = 5). Overall, tisagenlecleucel was tolerable in this population, with only 3 patients experiencing ≥grade 3 cytokine release syndrome. No neurotoxicity was reported. This is the largest report of tisagenlecleucel use in infant B-ALL and shows that this therapy is safe and can be effective in this population. Incorporating this novel immunotherapy into the treatment of infant B-ALL offers a promising therapy for a highly aggressive leukemia.

Journal Title

Blood Adv

Volume

6

Issue

14

First Page

4251

Last Page

4255

MeSH Keywords

Antigens, CD19; Child; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Retrospective Studies; United States

Keywords

CD19 Antigens; Precursor Cell Lymphoblastic Leukemia-Lymphoma; T-Cell Antigen Receptors; Chimeric Antigen Receptors; Retrospective Studies; United States

Comments

This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.

Publisher's Link: https://ashpublications.org/bloodadvances/article/6/14/4251/485283/Real-world-use-of-tisagenlecleucel-in-infant-acute

Share

COinS